Induced pluripotent stem cells as a model for therapy personalization of pediatric patients: disease modeling and drug adverse effects prevention

Elena Genova, Marco Pelin, Katsunori Sasaki, Yue Fengming, Gaetana Lanzi, Stefania Masneri, Alessandro Ventura, Gabriele Stocco, Giuliana Decorti

Research output: Contribution to journalArticle

Abstract

Understanding the biological and molecular processes underlying human pathologies is fundamental in order to develop innovative approaches to treat or prevent them. Among the technologies that could provide innovative disease models, induced pluripotent stem cells (iPSCs) is one of the most promising. Indeed, one application of iPSCs technology is personalized disease modeling. These cells, obtained by reprogramming patients' cells collected from accessible tissues, have the unique capability to differentiate, under an adequate stimulus, into any human cell type. In particular, iPSCs technology can be applied to study (human) drug toxicity, that is a key part of the drug discovery process. Indeed, drug induced adverse effects are among the most common causes that lead to abandon the development of new candidate therapeutic molecules, increasing the cost of drug discovery. An innovative strategy that could be used in drug design to solve drug attrition rate, and to establish innovative pharmacological models, could be the application of iPSCs technology in the early stage of the drug discovery process to model drug-induced adverse events. In this review, recently developed disease models based on iPSCs will be discussed, with a particular focus on available models of drugs' adverse effect, in particular hepatic/pancreatic toxicity.

Original languageEnglish
JournalCurrent Medicinal Chemistry
DOIs
Publication statusE-pub ahead of print - Aug 4 2017

Fingerprint

Induced Pluripotent Stem Cells
Pediatrics
Drug Design
Stem cells
Drug Discovery
Technology
Pharmaceutical Preparations
Drug-Related Side Effects and Adverse Reactions
Toxicity
Biological Phenomena
Therapeutics
Pathology
Pharmacology
Costs and Cost Analysis
Cells
Tissue
Liver
Molecules
Costs

Cite this

Induced pluripotent stem cells as a model for therapy personalization of pediatric patients : disease modeling and drug adverse effects prevention. / Genova, Elena; Pelin, Marco; Sasaki, Katsunori; Fengming, Yue; Lanzi, Gaetana; Masneri, Stefania; Ventura, Alessandro; Stocco, Gabriele; Decorti, Giuliana.

In: Current Medicinal Chemistry, 04.08.2017.

Research output: Contribution to journalArticle

Genova, Elena ; Pelin, Marco ; Sasaki, Katsunori ; Fengming, Yue ; Lanzi, Gaetana ; Masneri, Stefania ; Ventura, Alessandro ; Stocco, Gabriele ; Decorti, Giuliana. / Induced pluripotent stem cells as a model for therapy personalization of pediatric patients : disease modeling and drug adverse effects prevention. In: Current Medicinal Chemistry. 2017.
@article{ecc3b3092e4a49698d665b8cb260d8fe,
title = "Induced pluripotent stem cells as a model for therapy personalization of pediatric patients: disease modeling and drug adverse effects prevention",
abstract = "Understanding the biological and molecular processes underlying human pathologies is fundamental in order to develop innovative approaches to treat or prevent them. Among the technologies that could provide innovative disease models, induced pluripotent stem cells (iPSCs) is one of the most promising. Indeed, one application of iPSCs technology is personalized disease modeling. These cells, obtained by reprogramming patients' cells collected from accessible tissues, have the unique capability to differentiate, under an adequate stimulus, into any human cell type. In particular, iPSCs technology can be applied to study (human) drug toxicity, that is a key part of the drug discovery process. Indeed, drug induced adverse effects are among the most common causes that lead to abandon the development of new candidate therapeutic molecules, increasing the cost of drug discovery. An innovative strategy that could be used in drug design to solve drug attrition rate, and to establish innovative pharmacological models, could be the application of iPSCs technology in the early stage of the drug discovery process to model drug-induced adverse events. In this review, recently developed disease models based on iPSCs will be discussed, with a particular focus on available models of drugs' adverse effect, in particular hepatic/pancreatic toxicity.",
author = "Elena Genova and Marco Pelin and Katsunori Sasaki and Yue Fengming and Gaetana Lanzi and Stefania Masneri and Alessandro Ventura and Gabriele Stocco and Giuliana Decorti",
note = "Copyright{\circledC} Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",
year = "2017",
month = "8",
day = "4",
doi = "10.2174/0929867324666170804150131",
language = "English",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Induced pluripotent stem cells as a model for therapy personalization of pediatric patients

T2 - disease modeling and drug adverse effects prevention

AU - Genova, Elena

AU - Pelin, Marco

AU - Sasaki, Katsunori

AU - Fengming, Yue

AU - Lanzi, Gaetana

AU - Masneri, Stefania

AU - Ventura, Alessandro

AU - Stocco, Gabriele

AU - Decorti, Giuliana

N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

PY - 2017/8/4

Y1 - 2017/8/4

N2 - Understanding the biological and molecular processes underlying human pathologies is fundamental in order to develop innovative approaches to treat or prevent them. Among the technologies that could provide innovative disease models, induced pluripotent stem cells (iPSCs) is one of the most promising. Indeed, one application of iPSCs technology is personalized disease modeling. These cells, obtained by reprogramming patients' cells collected from accessible tissues, have the unique capability to differentiate, under an adequate stimulus, into any human cell type. In particular, iPSCs technology can be applied to study (human) drug toxicity, that is a key part of the drug discovery process. Indeed, drug induced adverse effects are among the most common causes that lead to abandon the development of new candidate therapeutic molecules, increasing the cost of drug discovery. An innovative strategy that could be used in drug design to solve drug attrition rate, and to establish innovative pharmacological models, could be the application of iPSCs technology in the early stage of the drug discovery process to model drug-induced adverse events. In this review, recently developed disease models based on iPSCs will be discussed, with a particular focus on available models of drugs' adverse effect, in particular hepatic/pancreatic toxicity.

AB - Understanding the biological and molecular processes underlying human pathologies is fundamental in order to develop innovative approaches to treat or prevent them. Among the technologies that could provide innovative disease models, induced pluripotent stem cells (iPSCs) is one of the most promising. Indeed, one application of iPSCs technology is personalized disease modeling. These cells, obtained by reprogramming patients' cells collected from accessible tissues, have the unique capability to differentiate, under an adequate stimulus, into any human cell type. In particular, iPSCs technology can be applied to study (human) drug toxicity, that is a key part of the drug discovery process. Indeed, drug induced adverse effects are among the most common causes that lead to abandon the development of new candidate therapeutic molecules, increasing the cost of drug discovery. An innovative strategy that could be used in drug design to solve drug attrition rate, and to establish innovative pharmacological models, could be the application of iPSCs technology in the early stage of the drug discovery process to model drug-induced adverse events. In this review, recently developed disease models based on iPSCs will be discussed, with a particular focus on available models of drugs' adverse effect, in particular hepatic/pancreatic toxicity.

U2 - 10.2174/0929867324666170804150131

DO - 10.2174/0929867324666170804150131

M3 - Article

C2 - 28782468

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

ER -